Neotron now able to detect nitrosamines in APIs and drugs

The European Medicines Agency (EMA) recently issued advice to pharmaceutical companies on how to avoid the presence of nitrosamines in medicines. Nitrosamines are classified as probable human carcinogens and the EMA has asked manufacturers of medicines made with chemically synthesized active pharmaceutical ingredients (APIs) to test their products for the possible presence of such impurities.

In response to this crisis and in support of the pharmaceutical industry, Neotron Pharma GMP Lab, part of the Cotecna Group, has developed an effective analytical method which can detect nitrosamines in APIs and drugs.

To learn more, please download the full report published by Neotron, or contact customerservice.pharma@neotron.it 

About Cotecna

For over 50 years, we have been supporting agriculture, food and pharma, minerals and metals, and consumer products supply chains all over the world. We provide testing, inspection, and certification services to help our clients navigate evolving regulations, ensure product compliance, and support their sustainability journey.